174 related articles for article (PubMed ID: 28887769)
1. α-Synuclein Interacts with Lipoproteins in Plasma.
Emamzadeh FN; Allsop D
J Mol Neurosci; 2017 Oct; 63(2):165-172. PubMed ID: 28887769
[TBL] [Abstract][Full Text] [Related]
2. Structural and Functional Changes of Reconstituted High-Density Lipoprotein (HDL) by Incorporation of α-synuclein: A Potent Antioxidant and Anti-Glycation Activity of α-synuclein and apoA-I in HDL at High Molar Ratio of α-synuclein.
Cho KH
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946565
[TBL] [Abstract][Full Text] [Related]
3. High-density lipoprotein-like particle formation of Synuclein variants.
Eichmann C; Kumari P; Riek R
FEBS Lett; 2017 Jan; 591(2):304-311. PubMed ID: 28027392
[TBL] [Abstract][Full Text] [Related]
4. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.
Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2019 Jul; 127():163-177. PubMed ID: 30849508
[TBL] [Abstract][Full Text] [Related]
5. Alpha synuclein is transported into and out of the brain by the blood-brain barrier.
Sui YT; Bullock KM; Erickson MA; Zhang J; Banks WA
Peptides; 2014 Dec; 62():197-202. PubMed ID: 25278492
[TBL] [Abstract][Full Text] [Related]
6. Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.
Emamzadeh FN
J Mol Neurosci; 2017 Aug; 62(3-4):344-355. PubMed ID: 28695482
[TBL] [Abstract][Full Text] [Related]
7. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
Xu S; Chan P
Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
[TBL] [Abstract][Full Text] [Related]
8. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
[TBL] [Abstract][Full Text] [Related]
9. Interactions of Lipids, Lipoproteins, and Apolipoproteins with the Blood-Brain Barrier.
Rhea EM; Banks WA
Pharm Res; 2021 Sep; 38(9):1469-1475. PubMed ID: 34518942
[TBL] [Abstract][Full Text] [Related]
10. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoproteins.
Mahley RW; Innerarity TL; Weisgraber KB; Oh SY
J Clin Invest; 1979 Sep; 64(3):743-50. PubMed ID: 224077
[TBL] [Abstract][Full Text] [Related]
11. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
[TBL] [Abstract][Full Text] [Related]
12. Brain disposition of α-Synuclein: roles of brain barrier systems and implications for Parkinson's disease.
Bates CA; Zheng W
Fluids Barriers CNS; 2014; 11():17. PubMed ID: 25093076
[TBL] [Abstract][Full Text] [Related]
13. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease.
Wang X; Yu S; Li F; Feng T
Neurosci Lett; 2015 Jul; 599():115-9. PubMed ID: 25998655
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease.
Foulds PG; Mitchell JD; Parker A; Turner R; Green G; Diggle P; Hasegawa M; Taylor M; Mann D; Allsop D
FASEB J; 2011 Dec; 25(12):4127-37. PubMed ID: 21865317
[TBL] [Abstract][Full Text] [Related]
15. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
Sato H; Kato T; Arawaka S
Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells.
Yeo S; Sung B; Hong YM; van den Noort M; Bosch P; Lee SH; Song J; Park SK; Lim S
Gene; 2018 Jun; 661():189-195. PubMed ID: 29604467
[TBL] [Abstract][Full Text] [Related]
17. Elevated ApoE, ApoJ and lipoprotein-bound α-synuclein levels in cerebrospinal fluid from Parkinson's disease patients - Validation in the BioFIND cohort.
Paslawski W; Svenningsson P
Parkinsonism Relat Disord; 2023 Nov; 116():105765. PubMed ID: 37479568
[TBL] [Abstract][Full Text] [Related]
18. A Comparative Study of the Diagnostic Potential of Plasma and Erythrocytic α-Synuclein in Parkinson's Disease.
Wang L; Wang G; Duan Y; Wang F; Lin S; Zhang F; Li H; Li A; Li H
Neurodegener Dis; 2019; 19(5-6):204-210. PubMed ID: 32485710
[TBL] [Abstract][Full Text] [Related]
19. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
20. Alpha-Synuclein Dopaminylation Presented in Plasma of Both Healthy Subjects and Parkinson's Disease Patients.
Zhao H; Huang S; Palanisamy S; Wang C; Rainer G; Zhang X
Proteomics Clin Appl; 2020 Sep; 14(5):e1900117. PubMed ID: 32538547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
